Ye Pingting, Feng Lei, Shi Shuo, Dong Chunyan
Department of Oncology, Shanghai East Hospital, School of Medicine, Shanghai Key Laboratory of Chemical Assessment and Sustainability, School of Chemical Science and Engineering, Tongji University, Shanghai 200120, China.
Cancers (Basel). 2022 Apr 23;14(9):2101. doi: 10.3390/cancers14092101.
Breast cancer (BC) is a highly heterogeneous disease and presents a great threat to female health worldwide. Chemotherapy is one of the predominant strategies for the treatment of BC; however, multidrug resistance (MDR) has seriously affected or hindered the effect of chemotherapy. Recently, a growing number of studies have indicated that lncRNAs play vital and varied roles in BC chemoresistance, including apoptosis, autophagy, DNA repair, cell cycle, drug efflux, epithelial-mesenchymal transition (EMT), epigenetic modification and the tumor microenvironment (TME). Although thousands of lncRNAs have been implicated in the chemoresistance of BC, a systematic review of their regulatory mechanisms remains to be performed. In this review, we systematically summarized the mechanisms of MDR and the functions of lncRNAs mediated in the chemoresistance of BC from the latest literature. These findings significantly enhance the current understanding of lncRNAs and suggest that they may be promising prognostic biomarkers for BC patients receiving chemotherapy, as well as therapeutic targets to prevent or reverse chemoresistance.
乳腺癌（BC）是一种高度异质性疾病，对全球女性健康构成巨大威胁。化疗是治疗BC的主要策略之一；然而，多药耐药（MDR）严重影响或阻碍了化疗效果。近年来，越来越多的研究表明，长链非编码RNA（lncRNAs）在BC化疗耐药中发挥着至关重要且多样的作用，包括细胞凋亡、自噬、DNA修复、细胞周期、药物外排、上皮-间质转化（EMT）、表观遗传修饰以及肿瘤微环境（TME）。尽管已有数千种lncRNAs与BC的化疗耐药相关，但对其调控机制仍有待进行系统综述。在本综述中，我们从最新文献中系统总结了MDR的机制以及lncRNAs在BC化疗耐药中介导的功能。这些发现显著加深了当前对lncRNAs的理解，并表明它们可能是接受化疗的BC患者有前景的预后生物标志物，也是预防或逆转化疗耐药的治疗靶点。
Zotero 插件
